<DOC>
	<DOCNO>NCT01907867</DOCNO>
	<brief_summary>This study investigate safety , tolerability , PK profile finafloxacin novel fluoroquinolone potential therapeutic agent low respiratory infection bacterial pneumonia . A comparison PK profile finafloxacin plasma lung ELF use different bronchoscopic ELF sample technique ( BMS BAL ) conduct .</brief_summary>
	<brief_title>Pharmacokinetic Profile Plasma Epithelial Lining Fluid Finafloxacin</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>1 . Able provide write informed consent ; 2 . Age ≥18 year ≤55 year ; 3 . Male female healthy volunteer ; 4 . Body mass index ( BMI ) ≥18.0 kg/m2 ≤30.0 kg/m2 body weight ≥48 kg ≤100 kg ; 5 . Women childbearing potential must negative urine pregnancy test confirm Screening study enrollment , must breastfeed , must use effective method contraception least 1 month enrollment 3 month follow completion study : A woman childbearing potential define female subject experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( defined woman age 50 amenorrheic least 12 consecutive month ) ; Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , whose partner sterile ( e.g . vasectomy ) consider childbearing potential ; 6 . If male subject 's sexual partner childbearing potential , male subject must acknowledge use acceptable method contraception ( define ) first dose study drug 3 month last dosing occasion prevent pregnancy ; 7 . Expectation , judgment Investigator , subject complete study activity ; 8 . Willing comply study activity procedures throughout duration study . 1 . Known chronic medical condition , include respiratory condition asthma chronic obstructive pulmonary disease , cardiovascular condition hypertension coronary artery disease ; 2 . Prolongation correct QT interval ( QTcB ) rest , mean QTcB interval &gt; 500 msec base triplicate ECG Screening ; 3 . Use tobacco product within 6 month Screening ; 4 . Women pregnant breastfeeding ; 5 . Receipt investigational medication last month ( 30 day 5 halflives , whichever long ) prior enrollment ; 6 . Prior exposure finafloxacin ; 7 . Use concomitant medication ( include overthecounter drug , vitamin , antacid ) within 7 day prior study drug administration study ( acetaminophen allow ) ; 8 . Any disorder may interfere evaluation study drug ; 9 . Known hypersensitivity finafloxacin fluoroquinolone ; 10 . Donated blood , plasma , platelets 3 month prior enrollment 2 occasion within 12 month precede first dose study drug ; 11 . Known history tendon rupture tendonitis ; 12 . A positive urine drug screen breath alcohol test result Screening enrollment ; 13 . Known viral hepatitis , positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody , positive Human Immunodeficiency Virus ( HIV ) antibodies ; 14 . Clinically significant abnormal laboratory value Screening enrollment ; 15 . Unable unwilling , judgment Investigator , comply protocol ; 16 . An employee Investigator study site direct involvement propose study study direction Investigator study site , family member site employee Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>